Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,317 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Diseases Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Study of LP-184 in Patients With Advanced Solid Tumors

NCT05933265
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
Interventions
LP-184, Olaparib, Nivolumab & Ipilimumab
Drug
Lead sponsor
Lantern Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

NCT02331251
View directory record Official record
Conditions
Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
Interventions
Pembrolizumab, Gemcitabine, Docetaxel, Nab-paclitaxel, Vinorelbine, Irinotecan, Liposomal Doxorubicin
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis

NCT04687475
View directory record Official record
Conditions
Cystic Fibrosis, Lung Transplant; Complications
Interventions
Clinical Tool (Mobile Spirometry and Survey)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Home Testing of Day and Night Closed Loop With Pump Suspend Feature

NCT02523131
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions
FlorenceM, Medtronic insulin pump 640G
Device
Lead sponsor
University of Cambridge
Other
Eligibility
6 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Omadacycline in Cystic Fibrosis

NCT04460586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet [Nuzyra]
Drug
Lead sponsor
Paul Beringer
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

NCT00401570
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Volociximab, Gemcitabine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 3, 2026, 10:59 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

NCT01374451
View directory record Official record
Conditions
Islet Cell Tumor
Interventions
Everolimus, Pasireotide LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • The Bronx, New York • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas

NCT00003951
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
exatecan mesylate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Surgically Resected Pancreatic Cancer

NCT00255827
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HyperAcute-Pancreatic Cancer Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 3, 2026, 10:59 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis

NCT00006273
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 10 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1996
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of HFCWO Vests on Spirometry Measurements

NCT03628456
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
International Biophysics AffloVest, Hill-Rom Monarch
Device
Lead sponsor
International Biophysics Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kissimmee, Florida
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

NCT03023722
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
anetumab ravtansine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • New Brunswick, New Jersey • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 3, 2026, 10:59 AM EDT
Completed No phase listed Observational

Acute Pancreatitis Patient Registry To Examine Novel Therapies In Clinical Experiences 2

NCT03075631
View directory record Official record
Conditions
Pancreatitis
Interventions
Questionnaire
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01064622
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03489590
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PFP
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 3, 2026, 10:59 AM EDT
Not listed No phase listed Observational

A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis

NCT04743323
View directory record Official record
Conditions
Pancreatitis, Acute, Alcohol Drinking, Health Behavior
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

NCT03098550
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Daratumumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) With Different Food Choices in the Outpatient Setting

NCT03767790
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
iAPS
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction

NCT00688662
View directory record Official record
Conditions
Sphincter of Oddi Dysfunction
Interventions
ERCP with sphincterotomy, ERCP without sphincterotomy
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
7
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 3, 2026, 10:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

NCT05055323
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
Interventions
Pyrvinium Pamoate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Active, not recruiting Phase 2 Interventional

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

NCT06519097
View directory record Official record
Conditions
Neoplasm of Pancreas, IPMN, Pancreatic
Interventions
Vitamin E Delta Tocotrienol, Placebo
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas

NCT00003923
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
Interventions
porfimer sodium
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 3, 2026, 10:59 AM EDT
Terminated Not applicable Interventional

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

NCT01241942
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 3, 2026, 10:59 AM EDT